
    
      This is a randomized, double-blind, pilot study of a total of 44 subjects with AD (22 with
      intrinsic and 22 with extrinsic AD) consisting of 2 phases. Subjects will be randomized (2:1)
      to either receive secukinumab 300 mg or placebo via subcutaneous injection using 2 prefilled
      syringes.
    
  